AtaiBeckley Inc. (NASDAQ:ATAI) earns a place on our list of the top 10 stocks under $5 that could triple. Analysts are ...
AtaiBeckley Inc (NASDAQ:ATAI) is among the best psychedelic stocks to buy in 2026. On March 17, AtaiBeckley Inc (NASDAQ:ATAI) ...
Inclusion in U.S. CRSP® benchmark indices triggers mandatory position-building by passive index funds tracking more than $3 trillion in AUM, ...
Why AtaiBeckley (ATAI) is on investors’ radar today AtaiBeckley (ATAI) has attracted fresh attention after a period of mixed ...
NEW YORK and AMSTERDAM, Oct. 20, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) ("atai"), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health ...
AtaiBeckley is a clinical-stage psychedelic biotech targeting TRD and SAD, with BPL-003 as its lead value driver. Learn more ...
Atai Life Sciences (NASDAQ: ATAI), a biotech focused on developing psychedelic-based medicines to treat mental health disorders, was a standout stock over the past few days in its rather limited peer ...
That drug, tagged BPL-003 by Atai, is an antidepressant that was recently evaluated in an open-label phase 2a study. The company is developing the medication in collaboration with a privately held ...
Invyxis will add proven medicinal chemistry and comprehensive biological evaluation capabilities to grow atai’s portfolio of new chemical entities (NCEs) Early focus will be on designing unique, novel ...
atai's mission is to tackle the significant unmet needs and lack of innovation in the treatment landscape by working with psychedelic and non-psychedelic compounds. atai is one of the leading ...
Clinical stage biopharma company atai Life Sciences ATAI announced the initiation of the Phase 1 proof-of-concept (PoC) clinical trial of intranasal INB-01, a sol-gel based, excipient (drug delivery) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results